Candriam Luxembourg S.C.A. boosted its position in Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 125.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,488,069 shares of the biotechnology company’s stock after buying an additional 828,069 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Pieris Pharmaceuticals were worth $5,387,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in Pieris Pharmaceuticals in the 2nd quarter valued at $47,000. Metropolitan Life Insurance Co NY purchased a new position in Pieris Pharmaceuticals in the 3rd quarter valued at $61,000. Meeder Asset Management Inc. grew its position in Pieris Pharmaceuticals by 450.6% in the 3rd quarter. Meeder Asset Management Inc. now owns 23,413 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 19,161 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in Pieris Pharmaceuticals by 25.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,177 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 4,290 shares during the last quarter. Finally, NJ State Employees Deferred Compensation Plan purchased a new position in Pieris Pharmaceuticals in the 3rd quarter valued at $102,000. Hedge funds and other institutional investors own 52.91% of the company’s stock.
A number of research firms recently weighed in on PIRS. Zacks Investment Research lowered shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 25th. William Blair reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Monday, November 11th. HC Wainwright lifted their price objective on shares of Pieris Pharmaceuticals from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, ValuEngine lowered shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $5.83.
Shares of NASDAQ PIRS opened at $3.73 on Friday. The firm has a market capitalization of $227.05 million, a P/E ratio of -5.33 and a beta of 1.28. Pieris Pharmaceuticals Inc has a one year low of $2.70 and a one year high of $6.04. The company’s fifty day moving average is $3.54 and its two-hundred day moving average is $3.96.
Pieris Pharmaceuticals Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: volatile stocks
Want to see what other hedge funds are holding PIRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pieris Pharmaceuticals Inc (NASDAQ:PIRS).
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.